Stockpolly
Search
Delisting risk
YARW · NASDAQ · Biotechnology

Yarrow Bioscience (YARW)

Develops a TSHR-blocking antibody for Graves’ disease and thyroid eye disease.

$29.83
At close−1.15 (−3.71%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue00000000000
Cost of revenue00000000000
Gross profit00000000000
77111313988543
Research & development3471010655311
44333333232
General & administrative04333333232
Other expenses00000000000
Operating income−7−7−10−13−13−9−8−8−5−4−3
11111120000
Other non-operating income−1−1−1−1−1−1−20000
Income before tax−6−6−9−12−12−9−6−7−5−4−3
Income tax expense00000000000
Net income from continuing operations−6−6−9−12−12−9−6−7−5−4−3
Discontinued operations00000000000
Net income−6−6−9−12−12−9−6−7−5−4−3
EPS, basic−$9.96−$7.33−$11.03−$14.27−$14.11−$10.09−$6.73−$8.50−$7.26−$4.19−$3.50
EPS, diluted−$9.96−$7.33−$11.03−$14.27−$14.11−$10.09−$6.73−$8.50−$7.26−$4.19−$3.50
Weighted average shares, basic11111111111
Weighted average shares, diluted11111111111
EBITDA−6−6−8−12−12−9−6−7−5−4−3
Depreciation & amortization00100000000
EBIT−6−6−9−12−12−9−6−7−5−4−3